Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to understand and have the ability to provide written consent~2. Age \> 18 years old to \<80 years old~3. Patients with AML in the first morphologic relapse as defined by \>5% reappearance of leukemia blasts in the bone marrow not attributable to any other cause (Appendix I) who have not yet received chemotherapy for the current relapse~4. Eastern Cooperative Oncology Group Performance Status of 0 -2 (see Appendix II)~5. Adequate organ function~   1. Serum creatinine ≤ 1.5 mg/dl and calculated creatinine clearance ≥ 50 mL/min (using the Cockcroft-Gault equation CL creatinine = (140-age) x body mass X 0.85 if female)/72 x creatinine where age is given in years, body mass is given in kg and creatinine is given in mg/dL)~  2. Aspartate aminotransferase (AST) ≤ 5x the upper limit of normal Alanine aminotransferase (ALT) \< 5x the upper limit of normal~  3. Direct bilirubin ≤ 1.5 mg/dl Note: As many eligible patients will be pancytopenic secondary to their disease or prior treatments, hematologic abnormalities will not be used as a criteria for entry or exclusion~6. Left ventricular ejection fraction (LVEF) ≥50 %~7. Females of child-bearing potential must have a negative pregnancy test during screening and all subjects must agree to use an effective method of contraception. A woman is eligible to enter and participate in the study if she is of:~   1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any female who has had a hysterectomy or has had a bilateral oophorectomy (ovariectomy).~  2. Childbearing potential, has a negative serum pregnancy test during the screening period and agrees to avoid sexual activity or use accepted methods of contraception from screening through follow-up.~Men with a female partner of childbearing potential are eligible to enroll and participate in the study if they have had either a prior vasectomy or agree to avoid sexual activity or use appropriate barrier contraception from screening through post-treatment follow-up.~Exclusion Criteria:~1. Acute promyelocytic leukemia~2. Prior chemotherapy regimen given for 1st relapse, not including the use of hydroxyurea or plasmapheresis that is used prior to the initiation of chemotherapy.~3. Previous use of mitoxantrone and etoposide combination therapy within the preceding 180 days of screening.~4. Symptomatic central nervous system (CNS) involvement~5. Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy~6. History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent~7. Current receiving any other anti neoplastic investigational agents~8. Prior autologous or allogeneic stem cell transplantation~9. Concurrent malignancy. Exceptions: Patients who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with concurrent malignancies that are indolent or definitely treated may be enrolled.~10. Women who are pregnant or breastfeeding~11. Evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory or cardiac disease)~12. Inability to take oral medications, due to impaired swallowing ability or poor absorption capacity~13. Known glucose-6-phosphate dehydrogenase (G-6PD) deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Open-label, Single-arm (Type: EXPERIMENTAL): Hydroxychloroquine + Mitoxantrone + Etoposide~Hydroxychloroquine is given up to 21 days, started concurrently with both Mitoxantrone, administered by IVPB over 15 minutes each day for 5 days and Etoposide, administered intravenously over 2 hours each day for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).